CC
| |
COMMODORE CAPITAL LP13F | |
| COMMODORE CAPITAL LP | |
| Last update 2025-05-15 | 31 Stocks (4 new) |
| Value $1.36 Bil | Turnover 22 % |
COMMODORE CAPITAL LP Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRUS | Merus NV | 4,472,840 | 188,261.8 | +15.45% | 13.870 | +1.86% | 6.460 | +53.44% | +52.64% | 4,780.3 | Biotechnology | |
NUVL | Nuvalent Inc | 1,855,000 | 131,556.6 | +14.39% | 9.690 | +1.22% | 2.580 | +10.65% | +2.77% | 5,777.0 | Biotechnology | |
ELVN | Enliven Therapeutics Inc | 4,675,000 | 92,004.0 | +11.18% | 6.780 | +0.68% | 9.530 | +24.14% | -1.96% | 1,301.3 | Biotechnology | |
SLNO | Soleno Therapeutics Inc | 1,150,000 | 82,167.5 | -24.59% | 6.050 | -1.23% | 2.280 | +19.63% | +92.35% | 4,560.5 | Biotechnology | |
XENE | Xenon Pharmaceuticals Inc | 2,325,000 | 78,003.8 | -15.15% | 5.750 | -1.19% | 3.040 | -17.69% | -21.07% | 2,374.1 | Biotechnology | |
ALKS | Alkermes PLC | 1,950,000 | 64,389.0 | -15.22% | 4.740 | -0.74% | 1.180 | -0.07% | -5.67% | 4,473.8 | Drug Manufacturers | |
AGIO | Agios Pharmaceuticals Inc | 2,185,000 | 64,020.5 | New Holding | 4.720 | +4.72% | 3.770 | +42.26% | +22.82% | 2,337.5 | Biotechnology | |
PCVX | Vaxcyte Inc | 1,650,000 | 62,304.0 | +1.54% | 4.590 | +0.07% | 1.280 | +9.48% | -55.65% | 4,683.5 | Biotechnology | |
VERA | Vera Therapeutics Inc | 2,561,782 | 61,534.0 | +30.80% | 4.530 | +1.07% | 4.020 | +2.01% | -46.11% | 1,453.4 | Biotechnology | |
CLDX | Celldex Therapeutics Inc | 3,200,000 | 58,080.0 | New Holding | 4.280 | +4.28% | 4.820 | +20.66% | -7.22% | 1,556.6 | Biotechnology |
COMMODORE CAPITAL LP's Historical Top Holdings Breakdowns
COMMODORE CAPITAL LP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
AGIO | Agios Pharmaceuticals Inc | 2025-03-31 | New Buy New Buy | +4.72% | 29.3 ($33.17) 35.9 | $40.16 | 21.06% | New holding | 2,185,000 | 2,185,000 | |
CLDX | Celldex Therapeutics Inc | 2025-03-31 | New Buy New Buy | +4.28% | 18.15 ($22.34) 27.6 | $23.45 | 4.95% | New holding | 3,200,000 | 3,200,000 | |
SRRK | Scholar Rock Holding Corp | 2025-03-31 | Add Add | +1.88% | 32.15 ($38.47) 46.73 | $39.83 | 3.54% | Add 83.68% | 1,745,000 | 795,000 | |
MRUS | Merus NV | 2025-03-31 | Add Add | +1.86% | 39.01 ($43.61) 49.16 | $64.19 | 47.18% | Add 15.45% | 4,472,840 | 598,658 | |
SLDB | Solid Biosciences Inc | 2025-03-31 | New Buy New Buy | +1.59% | 2.88 ($4.28) 6.47 | $6.63 | 54.91% | New holding | 5,825,000 | 5,825,000 | |
SLNO | Soleno Therapeutics Inc | 2025-03-31 | Reduce Reduce | -1.23% | 42.54 ($48.69) 71.99 | $86.58 | 77.83% | Reduce -24.59% | 1,150,000 | -375,000 | |
NUVL | Nuvalent Inc | 2025-03-31 | Add Add | +1.22% | 67.38 ($78.19) 88.96 | $80.45 | 2.89% | Add 14.39% | 1,855,000 | 233,400 | |
VRDN | Viridian Therapeutics Inc | 2025-03-31 | Add Add | +1.19% | 13.48 ($17.03) 20.91 | $18.28 | 7.34% | Add 50% | 3,600,000 | 1,200,000 | |
XENE | Xenon Pharmaceuticals Inc | 2025-03-31 | Reduce Reduce | -1.19% | 33.55 ($37.97) 40.74 | $30.94 | -18.51% | Reduce -15.15% | 2,325,000 | -415,000 | |
VERA | Vera Therapeutics Inc | 2025-03-31 | Add Add | +1.07% | 24.02 ($32.13) 43.22 | $22.79 | -29.07% | Add 30.8% | 2,561,782 | 603,182 |
COMMODORE CAPITAL LP Total Holding History ($B)
COMMODORE CAPITAL LP's Asset Allocation
COMMODORE CAPITAL LP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
COMMODORE CAPITAL LP's Hypothetical Growth since 2025-03-31
COMMODORE CAPITAL LP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
COMMODORE CAPITAL LP's Holdings Heat Map
Size field:
COMMODORE CAPITAL LP's Holdings Bubble Chart
COMMODORE CAPITAL LP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers